OpGen (OPGN) Reports Q2 Loss of $0.84/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
OpGen Reports Second Quarter Financial Results and Provides Business Update
August 13, 2015 4:02 PM EDTGAITHERSBURG, Md., Aug. 13, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three and six months ended June 30, 2015. Highlights of the second quarter of 2015 and recent weeks include:
Acquisition of AdvanDx, Inc., a market leader in rapid molecular testing for microorganism identification Completion of a $6 million financing with Merck Global Health Innovation Fund, LLC (Merck GHI) Expansion and renewal of a... More